Analyst
Barclays
Equibles does not estimate personal net worth.
Balaji Prasad is recorded as Analyst at Barclays. Balaji Prasad has spoken on 4 earnings calls and 1 other investor event across 5 companies, most recently for Alvotech on June 4, 2026. Those appearances were for Alvotech (ALVO), Amneal Pharmaceuticals, Inc. (AMRX), Zoetis Inc. (ZTS), Teva Pharmaceutical Industries Ltd (TEVA) and Viatris Inc (VTRS). The companies whose calls Balaji Prasad spoke on are classified in the Healthcare sector.
“So it's great to see the consistent progress in the healthy outlook. I'll try to get a couple of questions on topics not asked, but Tassel, starting with you, firstly on the guidance and EBITDA margins, 2025 EBITDA range seems to be at around 20.9 to 22.5%.”
“Firstly, you clarified that none of the expected approvals within the next 12 months have been factored into the guidance.”
“Firstly, on the free cash flow decline this year in the guidance, nearly $200 to $500 million of decline. Can you quantify the impact of these accounts receivable securitization programs?”
“A couple of macro questions and a bookkeeping question from me on, firstly, emerging markets, it looks like this quarter has been largely driven by emerging markets.”
Barclays
Analyst
Source not stated
ALVO
Drug Manufacturers - Specialty & Generic · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
ZTS
Drug Manufacturers - Specialty & Generic · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
VTRS
Drug Manufacturers - Specialty & Generic · Healthcare
